HealthEconomy
News 0 of 32

Semaglutide Patent Expiry (March 2026) to Reduce GLP-1 Drug Costs by 80% for India's 101 Million Diabetics

Health & EducationEconomyScience & TechPolityHIGH
Target:UPSCMPSCTeachingPrelims HighMains High
26 Mar 2026
~2 min
Source: Indian Express
Key Data:March 20, 2026Over 101 million50-80%Rs 1,500–Rs 5,000Rs 8,500 to over Rs 16,000$10 billion
Practice MCQs from today's news ▸
What This Article Covers

1.The patent for semaglutide (GLP-1 receptor agonist) expired in India on March 20, 2026, opening the door for over 50 generic versions from 40+ domestic firms.

2.Generic competition is expected to slash monthly treatment costs from Rs 8,500-16,000 to Rs 1,500-5,000, making it accessible for India's 101 million Type II diabetics.

3.The regulatory challenge is to prevent misuse for cosmetic weight loss while ensuring these drugs are prescribed only by qualified specialists for approved clinical conditions.

The Big Picture
Prelims · HighMains · High

The patent expiry of semaglutide (the molecule in Ozempic/Wegovy) in March 2026 will flood the Indian market with affordable generic GLP-1 drugs, potentially cutting treatment costs by 80%. This is a pivotal public health moment for India, the diabetes capital of the world, with over 101 million patients, shifting the healthcare model from reactive to preventive care and reducing long-term national expenditure.

Exam Lens

Quick Exam Facts From News

Patent Expiry DateMarch 20, 2026
India's Diabetic PopulationOver 101 million
Cost Reduction (Projected)50-80%
Monthly Generic CostRs 1,500–Rs 5,000
US Export Potential$10 billion

1-Minute Revision

  • ›Patent Expiry Date: March 20, 2026
  • ›India's Diabetic Population: Over 101 million
  • ›Target this Data: Patent expiry date - March 20, 2026; Diabetic population - Over 101 million.
  • ›Target this Nodal Body: The drug regulator (Central Drugs Standard Control Organization - CDSCO) and major pharma firms like Sun Pharma, Dr. Reddy's.
  • ›Target this Legal Point: Patent law provisions and regulations against surrogate advertising for off-label drug promotion.

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

Q1Static LinkageEasy

The article mentions that major Indian pharmaceutical firms have moved to launch generic versions of semaglutide. Which of the following is NOT one of the firms mentioned?

Q2Statement-basedHard

Consider the following statements regarding the news on semaglutide patent expiry:

1. The patent for semaglutide expired in India on March 20, 2026, opening the market for generic versions.

2. Before patent expiry, the monthly treatment cost for branded GLP-1 drugs was between Rs 1,500 and Rs 5,000.

3. GLP-1 receptor agonists are complex peptide-based therapies that mimic natural hormones to regulate blood sugar and appetite.

Which of the statements given above is/are correct?

Q3Data-centricMedium

According to the article, what is the projected reduction in the cost of GLP-1 drug treatment in India following the entry of generic versions?

Q4Application/ImpactMedium

What is identified as the primary public health benefit of wider access to affordable generic GLP-1 drugs in India?

All 25 MCQs ▸
Read original article from Indian Express
You finished this topic
Practice 3 MCQs from this newsNext Article
Explore Related Topics
Health & EducationView Topic MCQs →EconomyView Topic MCQs →Science & TechView Topic MCQs →PolityView Topic MCQs →
Next India's 2035 NDC Targets: 60% Non-fossil Power, 47% Emission Intensity Cut, 4 Billion Tonne Carbon Sink
Related Current Affairs
Polity Current Affairs

SC Applies Section 498A to Live-in Relationships; NOTTO Launches Real-Time Organ Transplant Portal with Aadhaar Pledges

The Indian Express UPSC Key for August 4, 2026, covers multiple crucial topics: the Supreme Court's ruling extending Section 498A cruelty protection to live-in relationships, the launch of a real-time organ transplant portal by NOTTO, the Vikram Sarabhai Medal awarded to Annapurni Subramaniam, India's resilient fertiliser supply amid the Iran war, the science behind Europe's wildfires, and the Ceuta migrant crisis. These topics span Polity, Health, Science, Environment, and International Relations, offering direct material for UPSC Prelims and Mains.

Economy Current Affairs

India's E20 Fuel Mandate: 240 Million Legacy Vehicles Face Mileage Loss, Contamination Risks

India's nationwide E20 fuel mandate (20% ethanol blending) effective April 1, 2026, aims to reduce crude oil imports but raises serious concerns for 240 million legacy vehicles (pre-2023). Real-world mileage drops of over 10%, fuel system corrosion, phase separation, and contamination risks (chlorides up to 570 ppm, water up to 13,000 ppm) have sparked legal challenges and demands for consumer protection. This is a high-impact issue linking energy policy, automotive engineering, and consumer rights – a must-know for GS3 and GS2.

Science & Tech Current Affairs

India's R&D Spending, Patents Surge but Systemic Barriers Hinder Science Superpower Status: E-book

A Hindu e-book analyzes India's scientific trajectory, noting increased R&D spending and patent filings but flagging critical gaps: poor lab-to-market translation, bureaucratic hurdles, brain drain, and rising pseudoscience. For exams, this is a rich source of 'Challenges to India's Innovation Ecosystem' for GS3.

Science & Tech Current Affairs

Ministry of Mines Notifies 2 Offshore Mineral Blocks Near Great Nicobar for Polymetallic Nodules

India has notified two offshore mineral blocks near Great Nicobar Island for polymetallic nodule and crust exploration, strengthening its critical minerals push under the blue economy framework. This connects directly to the Deep Ocean Mission, Samudra Manthan scheme, UNCLOS, and India's strategic need for deep-sea mineral security. For exams, remember the Act, the minerals, the contracts, and the institutional framework.

Polity Current Affairs

RDI Fund: Govt Defends Conflict Safeguards; 62% of ₹2,192 Cr Loans Went to Panel-Linked Firms

The RDI Fund, created to support deep tech companies, faces controversy as 62% of first-round soft loans (₹2,192 crore) went to firms linked to selection panel members. The government defends safeguards including super-majority voting and 10% stake disqualification, noting the second cohort has only 1 of 13 such companies. Congress seeks a parliamentary review on August 13.

Science & Tech Current Affairs

₹2,192 Cr RDI Fund for Deep-Tech: Conflict of Interest in Selection Panel Raises Questions

The government's ₹2,192 crore Research, Development and Innovation (RDI) fund for deep-tech faces conflict of interest allegations: 15 of 22 selected firms have investment ties to panel members. The article argues that disclosure and recusal are insufficient and demands structural safeguards like wider selector pool, academic evaluators, and published conflict records.

Economy Current Affairs

₹2,000 Cr Deep-Tech Fund: 62% First Cohort Conflict-of-Interest Charge, Guardrails Explained

An op-ed by the Chief Economic Advisor defends the ₹2,000 crore deep-tech fund's first cohort against conflict-of-interest allegations, revealing that 62% of allocations went to firms linked to panel members. For aspirants, this highlights governance in public funds, the balance between expertise and probity, and the need to evaluate outcomes over process.

Economy Current Affairs

₹743.43 Cr Revenue Detected in 6 Months: Andhra AI-GST Model Wins National Acclaim at 6th Coordination Meet

Andhra Pradesh’s AI & Machine Learning-based GST administration model has been nationally acclaimed at the 6th National Co-ordination Meeting. The system detected ₹743.43 crore in revenue in just six months—more than double the previous manual process—and has sparked interest from several states. For exam aspirants, this is a key case study on AI in governance, tax administration reform, and state-level innovation.

Start Today's Quiz(25 Qs)